

50. Keim NL, Mares-Perlman JA 1984 Development of hepatic steatosis and essential fatty acid deficiency in rats with hypercaloric, fat-free parenteral nutrition. *J Nutr* 114:1807–1815
51. Goheen SC, Larkin EC, Rao GA 1983 Severe fatty liver in rats fed a fat-free ethanol diet, and its prevention by small amounts of dietary arachidonate. *Lipids* 18:285–290
52. Allardyce DB 1982 Cholestasis caused by lipid emulsions. *Surg Gynecol Obstet* 154:641–647
53. Cavicchi M, Crenn P, Beau P, Degott C, Boutron MC, Messing B 1998 Severe liver complications associated with long-term parenteral nutrition are dependent on lipid parenteral input. *Transplant Proc* 30:2547
54. Cavicchi M, Beau P, Crenn P, Degott C, Messing B 2000 Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. *Ann Intern Med* 132:525–532
55. Clayton PT, Whitfield P, Iyer K 1998 The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition. *Nutrition* 14:158–164
56. Chen WJ, Yeh SL, Huang PC 1996 Effects of fat emulsions with different fatty acid composition on plasma and hepatic lipids in rats receiving total parenteral nutrition. *Clin Nutr* 15:24–28
57. Zaman N, Tam YK, Jewell LD, Coutts RT 1997 Effects of intravenous lipid as a source of energy in parenteral nutrition associated hepatic dysfunction and lidocaine elimination: a study using isolated rat liver perfusion. *Biopharm Drug Dispos* 18:803–819
58. Fernandes G 1994 Dietary lipids and risk of autoimmune disease. *Clin Immunol Immunopathol* 72:193–197
59. Burdge GC, Finnegan YE, Minihane AM, Williams CM, Wootton SA 2003 Effect of altered dietary n-3 fatty acid intake upon plasma lipid fatty acid composition, conversion of [<sup>13</sup>C]alpha-linolenic acid to longer-chain fatty acids and partitioning towards beta-oxidation in older men. *Br J Nutr* 90:311–321
60. Neschen S, Moore I, Regittig W, Yu CL, Wang Y, Pypaert M, Petersen KF, Shulman GI 2002 Contrasting effects of fish oil and safflower oil on hepatic peroxisomal and tissue lipid content. *Am J Physiol* 282:E395–E401
61. Willumsen N, Hexeberg S, Skorve J, Lundquist M, Berge RK 1993 Docosahexaenoic acid shows no triglyceride-lowering effects but increases the peroxisomal fatty acid oxidation in liver of rats. *J Lipid Res* 34:13–22
62. Rustan AC, Nossen JO, Christiansen EN, Drevon CA 1988 Eicosapentaenoic acid reduces hepatic synthesis and secretion of triacylglycerol by decreasing the activity of acyl-coenzyme A:1,2-diacylglycerol acyltransferase. *J Lipid Res* 29:1417–1426
63. Nossen JO, Rustan AC, Gloppstad SH, Malbakken S, Drevon CA 1986 Eicosapentaenoic acid inhibits synthesis and secretion of triacylglycerols by cultured rat hepatocytes. *Biochim Biophys Acta* 879:56–65
64. Bellenger J, Bellenger S, Clement L, Mandard S, Diot C, Poisson JP, Narce M 2004 A new hypotensive polyunsaturated fatty acid dietary combination regulates oleic acid accumulation by suppression of stearoyl CoA desaturase 1 gene expression in the SHR model of genetic hypertension. *FASEB J* 18:773–775

## Erratum

The article, “Effect of Dietary Ribonucleotides on Infant Immune Status. Part 1: Humoral Responses,” by Joseph P. Schaller, Matthew J. Kuchan, Debra L. Thomas, Christopher T. Cordle, Timothy R. Winship, Rachael H. Buck, Geraldine E. Baggs, and J. Gary Wheeler (*Pediatric Research* 56: 883–890), contained several errors.

On page 886, right column, paragraph 1, the sentence beginning “Comparison of the RCFD ” should read: Comparison of the RCFD curves revealed statistically significant distribution differences only at 12-mo (FN different from F,  $p = 0.023$ ) using the Kolmogorov-Smirnov test (30).

On page 887, the third footnote in Table 3 should read: Different by a post hoc three-group RMA on the evaluable data subset for 6, 7, and 12 mo group X time interaction  $p = 0.0285$ .

On page 888, for the legend of Figure 1, the sentence beginning “Reverse cumulative distributions ” should read: Reverse cumulative distributions were different at 12 mo ( $\chi^2_{FN > F}$ ,  $p = 0.023$ ).

On page 889, right column, paragraph 2, the sentence beginning “In this regard, ” should read: In this regard, it is most interesting that significant differences in key indicators of immune function (poliovirus VN1 responses and subsets of T and NK cells) were identified not only between formula groups but also more often between breast-fed infants and those fed formula without ribonucleotides.

Table 2 had missing percentage values and is reprinted below.

**Table 2.** Demographic Variables in the F, FN, and HMF Groups\*

	F	FN	HMF
Subjects, <i>n</i> (%)	147	138	192
Male	62 (42)	61 (44)	104 (54)
Female	85 (58)	77 (56)	88 (46)
Ethnicity, <i>n</i> (%)			
Caucasian	126 (85.7)	119 (86.2)	170 (88.5)
African-American	14 (9.5)	14 (10.1)	12 (6.3)
Hispanic	1 (0.7)	1 (0.7)	4 (2.1)
Asian	0 (0.0)	1 (0.7)	0 (0.0)
Other	6 (4.1)	3 (2.2)	6 (3.1)
Gestational age (wk)†	39	39	39
Weight (g) at 10 d of age‡			
Male	3528 ± 66	3561 ± 67	3625 ± 51
Female	3535 ± 59	3397 ± 48	3509 ± 49
Maternal education, <i>n</i> (%)			
Some high school	11 (8)	9 (7)	5 (3)
High school	38 (27)	35 (26)	30 (16)
Some college	49 (34)	53 (39)	64 (33)
College or more	45 (31)	39 (28)	93 (48)

\* F, control; FN, ribonucleotide-supplemented; HMF, fed exclusively human milk for at least 2 months followed by human milk or commercial Similac with Iron at weaning.

† Values are mean [median].

‡ Values are mean ± SEM.